TURIN, Italy – (BUSINESS WIRE) – Resalis Therapeutics today announced a strategic equity investment from Sanofi. The company plans to use the proceeds to accelerate the development of its lead investigational candidate RES-010 through a Phase 2 proof-of-concept clinical trial. RES-010 represents a first-in-class antisense oligonucleotide that targets miR-22, a non-coding RNA that plays a pivotal role in the molecular pathways underlying obesity. This innovative approach could put Resalis at the forefront of next-generation treatments in metabolic diseases.
said Alessandro Toniolo, CEO of Resalis Therapeutics. “The treatment landscape for obesity is rapidly evolving, and Sanofi’s investment highlights the potential of our approach. In addition to validating the robust data we have generated, we are moving quickly through Phase 2 trials to bring potentially innovative treatments to patients living with obesity. I believe this will serve as an opportunity to further increase interest.”
About RES-010
RES-010 is designed to reprogram metabolic pathways, providing potential disease-modifying therapeutic effects including high-quality, sustained weight loss. By specifically targeting miR-22, a master regulator of lipid biosynthesis, mitochondrial function, and adipose tissue transformation, RES-010 provides an alternative to traditional approaches that often focus solely on reducing appetite. It has potential to go beyond obesity treatment. This targeted approach has the potential to provide more durable solutions that address the complex biological underpinnings of obesity. Modulation of these pathways can reduce fat mass across different body regions, including visceral fat and liver stores. With its solid preclinical results, RES-010 has the potential to complement and enhance the efficacy of existing anti-obesity drugs such as GLP-1 receptor agonists, providing a more comprehensive therapeutic solution. may magnify its effect.
About Lisalis Therapeutics
Resalis Therapeutics is dedicated to developing RNA-based therapeutics that address the root causes of complex metabolic disorders. Resalis Therapeutics leverages its deep expertise in non-coding RNA and lipid metabolism to advance RES-010. Strong preclinical data supports the rapid advancement of RES-010 through clinical trials, positioning Resalis Therapeutics as a leading player in the evolving landscape of obesity treatment. Resalis is currently backed by investors Claris Ventures and Sunstone Life Science Ventures, as well as private investors Italian Angels for Growth and Club degli Investitori.
For more information, please visit our website www.resalistherapeutics.com.
